1. Home
  2. PRT vs NEUP Comparison

PRT vs NEUP Comparison

Compare PRT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

HOLD

Current Price

$2.10

Market Cap

27.7M

Sector

Energy

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$3.56

Market Cap

23.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PRT
NEUP
Founded
2017
1996
Country
United States
United States
Employees
N/A
8
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
23.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRT
NEUP
Price
$2.10
$3.56
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
53.4K
97.9K
Earning Date
05-13-2026
05-23-2026
Dividend Yield
13.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$3.19
52 Week High
$4.14
$21.31

Technical Indicators

Market Signals
Indicator
PRT
NEUP
Relative Strength Index (RSI) 42.41 33.44
Support Level $1.87 $3.19
Resistance Level $2.36 $4.58
Average True Range (ATR) 0.10 0.33
MACD -0.00 -0.05
Stochastic Oscillator 32.36 26.15

Price Performance

Historical Comparison
PRT
NEUP

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: